Short-Course Immunotherapy Leads to Five Years Recurrence-Free in dMMR Colon Cancer

Long-term results from the NICHE-2 study, published in *The Lancet*, indicate that a short course of immunotherapy administered before surgery has kept all patients in the trial with non-metastatic mismatch repair-deficient (dMMR) colon cancer free of disease recurrence for five years. All 111 patients in the primary efficacy population were alive at their most recent follow-up, with a three-year disease-free survival rate of 100 percent and an estimated five-year overall survival rate also at 100 percent.